ARROWHEAD PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted of 165.00 thousand shares for the 6-month period ending 2014-03-31, per its 10-Q filed 2014-05-06.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted · last filed 2014-05-06
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2014-03-31 was 60.00K shares.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2013-12-31 was 105.00K shares.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2013-09-30 was -201.20K shares.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2013 was 50.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 12 month |
|---|---|---|---|---|
| 2014-03-31 | 60.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-05-06 | 165.00K shares 10-Q · filed 2014-05-06 | -36.20K shares derived: sum of 3 quarters · filed 2014-05-06 | |
| 2013-12-31 | 105.00K shares 10-Q · filed 2014-02-04 | -96.20K shares derived: sum of 2 quarters · filed 2014-02-04 | ||
| 2013-09-30 | -201.20K shares derived: 10-K 12 month − 10-Q 9 month · filed 2013-12-18 | 50.00K shares 10-K · filed 2013-12-18 | ||
| 2013-06-30 | 251.20K shares 10-Q · filed 2013-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |